1. Canada Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Waverley Pharma, Inc.

Waverley Pharma, Inc.

WAVE.V
Waverley Pharma, Inc.CA flagToronto Stock Exchange Ventures
0.01
CAD
- -
- -
540,000.00Market Cap
Waverley Pharma, Inc.
WAVE.V
(Toronto Stock Exchange Ventures)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.02
0.03
0.03
0.02
0.01
0.01
0.02
0.05
Revenue per Share
- -
-0.06
-0.03
-0.02
-0.01
-0.01
-0.01
-0.04
-0.02
-0.01
-0.02
Basic EPS, GAAP
- -
- -
-0.03
-0.03
-0.01
-0.01
- -
-0.02
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.09
0.07
0.05
0.04
0.03
0.02
-0.02
-0.04
-0.05
-0.05
Book Value per Share
- -
0.06
0.04
0.02
- -
- -
-0.01
-0.02
-0.05
-0.06
-0.06
Tangible Book Value per Share
40
43
54
54
54
54
54
54
54
54
54
Basic Weighted Avg Shares
- -
- -
- -
1
1
2
1
- -
- -
1
3
Sales/Revenue/Turnover
- -
- -
-664.6
-122.15
-51.6
-44.89
-51.18
-299.42
-156.42
-25.88
-21.24
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-2
-1
-1
-1
-1
-1
-2
-1
- -
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-635.95
-104.97
-51.32
-45.44
-53.26
-539.7
-199.23
-36.99
-31.97
Profit Margin (%)
- -
4
2
1
- -
- -
-1
-2
-3
-3
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
5
4
3
2
2
1
-1
-2
-3
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-31.47
-35.64
-28.88
-41.57
-46.11
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-30.07%
26.54%
Free Cash Flow
- -
74.08%
48.96%
Net Income, GAAP
- -
25.29%
-47.29%
Sales/Revenue/Turnover
- -
26.18%
183.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
1
1
1
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.02
- -
-0.02
2025
- -
- -
-0.01
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Ganga Pharmaceuticals Limited (GANGAPHARM.BO)
Radiko Holdings Corp (GEATF)
Boryung Corporation (003850.KS)
Invitae Corporation (0JDB.L)
Welcure Drugs & Pharmaceuticals Limited (WELCURE.BO)
Tiaan Consumer Ltd. (TIAANC.BO)
Business
Waverley Pharma Inc. is a Canadian pharmaceutical company that develops, licenses, acquires, and commercializes generic oncology and other prescription medications, with operations focused on Canada, the United States, and select international markets. Founded in 2015 and headquartered in Winnipeg, Manitoba, the company markets affordable medicines and healthcare options, with product activities spanning generic oncology drugs, including capecitabine, pemetrexed, bortezomib, and erlotinib, as well as related pharmaceutical distribution and pharmacy operations. Its business also includes the acquisition and integration of pharmacy assets, supported by credit facilities and licensing or market-authorization initiatives in North America and Europe. In recent years, Waverley Pharma has expanded through the acquisition of a US-based pharmacy, including C&R Pharmacy in West Liberty, Ohio, and has continued to pursue regulatory and commercial growth through tender awards, market authorizations, and product approvals in the United Kingdom and multiple European countries. The company also reported a CFO transition effective July 24, 2026, with director James Kinley named interim CFO following Haaris Uddin’s resignation.